CERo Therapeutics

Cellular Immunotherapy

Also RD solid tumors; CER/CAR T-cell RD hematologic cancer, RD solid tumors

CERo Therapeutics is developing cellular immunotherapies to create a new class of cancer therapeutics using recent insights from synthetic and T cell biology. Receptor mediated cell clearance is a method used daily by the body. CERo is creating chimeric engulfment receptor (CER) T cells, engineered T cells that recognize stress ligands found on the surface of tumor cells. Following recognition, the CER T cells are induced to kill the cancer cell and display tumor-associated antigens on their surface to further enhance the immune response. CERo’s first generation CER T cells are designed to recognise the phospholipid phosphatidylserine that is found on stressed cells. CERo’s platform also has the therapeutic potential to synergize with a variety of targeted therapies to improve patient outcomes.

Jobs: